Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome (MetS), and type 2 diabetes (T2DM) are metabolic disorders that belong to a highly prevalent disease cluster with a significant impact on public health worldwide. MetS is a complex condition characterized by metabolism perturbations that include glucose intolerance, insulin resistance, dyslipidaemia, associated pro-inflammatory state, and arterial hypertension. Because the components of MetS commonly co-occur, the management of these disorders cannot be considered separate issues. Thus NAFLD, recognized as a hepatic manifestation of MetS, is frequently associated with T2DM. This review analyses the underlying connections between these diseases and the risks associated with their co-occurrence. The effective management of NAFLD associated with MetS and T2DM involves an early diagnosis and optimal treatment of each condition leading to improvement in glycaemic and lipid regulation, liver steatosis, and arterial hypertension. The net effect of such treatment is the prevention of atherosclerotic cardiovascular diseases and liver fibrosis.

Mitrovic, B., Obradovic, M., Gluvic, Z., Radunovic, M., Rizzo, M., Banach, M., et al. (2022). Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?. ARCHIVES OF MEDICAL SCIENCE, 19(4) [10.5114/aoms/150639].

Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?

Rizzo, Manfredi;
2022-06-01

Abstract

Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome (MetS), and type 2 diabetes (T2DM) are metabolic disorders that belong to a highly prevalent disease cluster with a significant impact on public health worldwide. MetS is a complex condition characterized by metabolism perturbations that include glucose intolerance, insulin resistance, dyslipidaemia, associated pro-inflammatory state, and arterial hypertension. Because the components of MetS commonly co-occur, the management of these disorders cannot be considered separate issues. Thus NAFLD, recognized as a hepatic manifestation of MetS, is frequently associated with T2DM. This review analyses the underlying connections between these diseases and the risks associated with their co-occurrence. The effective management of NAFLD associated with MetS and T2DM involves an early diagnosis and optimal treatment of each condition leading to improvement in glycaemic and lipid regulation, liver steatosis, and arterial hypertension. The net effect of such treatment is the prevention of atherosclerotic cardiovascular diseases and liver fibrosis.
giu-2022
Settore MEDS-08/A - Endocrinologia
Mitrovic, B., Obradovic, M., Gluvic, Z., Radunovic, M., Rizzo, M., Banach, M., et al. (2022). Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?. ARCHIVES OF MEDICAL SCIENCE, 19(4) [10.5114/aoms/150639].
File in questo prodotto:
File Dimensione Formato  
AMS-19-4-150639.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 147.19 kB
Formato Adobe PDF
147.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/670923
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact